Phase II Study, Multicenter, Open-Label, Evaluating Efficacy of Treatment With Sutent(Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer metastases; Renal cancer
- Focus Therapeutic Use
- 04 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2009 Additional trial location (France) identified as reported by ClinicalTrials.gov.
- 30 Apr 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.